NASDAQ:BDRX Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free BDRX Stock Alerts $1.00 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$0.98▼$1.1150-Day Range$0.72▼$1.6252-Week Range$0.67▼$20.80Volume164,599 shsAverage Volume2.37 million shsMarket Capitalization$1.29 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Biodexa Pharmaceuticals alerts: Email Address Biodexa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside700.0% Upside$8.00 Price TargetShort InterestBearish14.70% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.13) to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.25 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBiodexa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiodexa Pharmaceuticals has received no research coverage in the past 90 days.Read more about Biodexa Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.70% of the outstanding shares of Biodexa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBiodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodexa Pharmaceuticals has recently increased by 183.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiodexa Pharmaceuticals does not currently pay a dividend.Dividend GrowthBiodexa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BDRX. Previous Next 0.6 News and Social Media Coverage Search Interest7 people have searched for BDRX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.Read more about Biodexa Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Biodexa Pharmaceuticals are expected to grow in the coming year, from ($0.13) to ($0.11) per share.Price to Book Value per Share RatioBiodexa Pharmaceuticals has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX)Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Read More BDRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDRX Stock News HeadlinesApril 30, 2024 | finance.yahoo.comBiodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual MeetingApril 30, 2024 | globenewswire.comBiodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual MeetingMay 9, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 26, 2024 | investorplace.comWhy Is Biodexa (BDRX) Up 70% Today?April 26, 2024 | finance.yahoo.comBiodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)April 26, 2024 | globenewswire.comBiodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)April 19, 2024 | globenewswire.comPreliminary Results for the Year Ended 31 December 2023April 3, 2024 | msn.com7 stocks to watch on Tuesday: CHX on SLB deal, managed care players and moreMay 9, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 3, 2024 | msn.comView reaches deal with Cantor Fitzgerald and RXR to become a private companyApril 2, 2024 | seekingalpha.comJob openings roughly flat in February, with prior month's print revised down - JOLTSApril 2, 2024 | msn.comU.S. factory orders rise more than forecast in FebruaryMarch 30, 2024 | uk.investing.comBiodexa reports promising brain cancer drug resultsMarch 28, 2024 | finanznachrichten.deBiodexa Pharmaceuticals Plc: Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain CancersMarch 28, 2024 | benzinga.comGold Gains 1%; Walgreens Narrows Earnings ForecastMarch 28, 2024 | msn.comUS Stocks Flat; Initial Jobless Claims Fall To 210,000March 18, 2024 | msn.comBiodexa Pharmaceuticals files to sell 1.28B shares for holdersMarch 1, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week FlatFebruary 23, 2024 | finanznachrichten.deBiodexa Pharmaceuticals PLC: Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D UpdateFebruary 23, 2024 | globenewswire.comBiodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D UpdateFebruary 9, 2024 | finanznachrichten.deBiodexa Pharmaceuticals PLC: Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma PatientsJanuary 22, 2024 | finanznachrichten.deBiodexa Pharmaceuticals PLC: Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024January 22, 2024 | finance.yahoo.comBiodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024December 25, 2023 | uk.finance.yahoo.comBiodexa Pharmaceuticals Plc (BDRX)December 21, 2023 | finance.yahoo.comBiodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment OptionDecember 19, 2023 | msn.comWhy Biodexa Pharmaceuticals (BDRX) Shares Are Getting HammeredDecember 11, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday TradingSee More Headlines Receive BDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BDRX CUSIPN/A CIK1643918 Webwww.midatechpharma.com Phone441235888300FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+700.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.06 Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$410,000.00 Price / Sales3.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.93 per share Price / Book0.25Miscellaneous Outstanding Shares1,290,000Free Float1,283,000Market Cap$1.29 million OptionableNot Optionable Beta1.53 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Stephen A. Stamp (Age 62)CEO, CFO, Company Secretary & Director Comp: $314.73kDr. Dmitry Zamoryakhin M.D. (Age 44)Chief Scientific Officer & Chief Medical Officer Comp: $297.69kDr. Daniel Palmer MBAPh.D., Vice President of TechnologyMs. Nicola TuckwellVP & Head of Clinical OperationsMs. Fiona SharpGroup Financial ControllerKey CompetitorsGRI BioNASDAQ:GRIPanbela TherapeuticsNASDAQ:PBLALucy Scientific DiscoveryNASDAQ:LSDINeuBase TherapeuticsNASDAQ:NBSESunshine BiopharmaNASDAQ:SBFMView All Competitors BDRX Stock Analysis - Frequently Asked Questions Should I buy or sell Biodexa Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biodexa Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BDRX shares. View BDRX analyst ratings or view top-rated stocks. What is Biodexa Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 1 year price objectives for Biodexa Pharmaceuticals' shares. Their BDRX share price targets range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 700.0% from the stock's current price. View analysts price targets for BDRX or view top-rated stocks among Wall Street analysts. How have BDRX shares performed in 2024? Biodexa Pharmaceuticals' stock was trading at $2.68 on January 1st, 2024. Since then, BDRX shares have decreased by 62.7% and is now trading at $1.00. View the best growth stocks for 2024 here. Are investors shorting Biodexa Pharmaceuticals? Biodexa Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 189,600 shares, an increase of 183.8% from the March 31st total of 66,800 shares. Based on an average daily trading volume, of 2,030,000 shares, the days-to-cover ratio is currently 0.1 days. View Biodexa Pharmaceuticals' Short Interest. When did Biodexa Pharmaceuticals' stock split? Shares of Biodexa Pharmaceuticals reverse split on the morning of Wednesday, July 5th 2023. The 1-80 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Biodexa Pharmaceuticals? Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BDRX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm Press348 million Americans lives to END as we know it?The Oxford ClubGold Set to EXPLODE!Gold Safe ExchangeObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
